Fig 2. Phenotypic characterization of circulating progenitor cells (CPC, CD45^dim, CD34^bright, CD133⁺) and circulating mature cells (CMC, CD45^-, CD34⁺, CD133^-) in healthy subjects (CTR) and in patients (PT).

(A,E) The percentage of CPC and CMC on CD14^- is similar in CTR and in PT. (B-C) The percentage of CD309⁺ (marker of endothelial differentiation) or BAP⁺ (osteogenic marker) cells on CPC in CTR and in PT. (D) The different BAP⁺/CD309⁺ ratio on CPC suggests that circulating progenitor cells in patients undergo a shift towards an osteogenic phenotype. (F-G) Histograms show the percentage of CD309⁺ or BAP⁺ on CMC in CTR and in PT. (H) The different CD309⁺ on CPC/CD309⁺ on CMC ratio suggests that patients have a lower vascular repair potential. Values are shown as mean ± SD. *p<0.05.